An open-label phase II trial for patients with various stages of NSCLC and other solid tumors is recruiting patients with NSCLC (EGFR exon 20 insertion, HER2-activating mutations) and other solid tumors with NRG1/ERBB gene fusions to be treated with tarloxotinib bromide (NCT03805841) [43]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.